---
schema_version: "secwatch.filing_event.v1"
accession: "0001553350-26-000007"
form_type: "8-K"
ticker: "TOI"
cik: "0001799191"
company_name: "Oncology Institute, Inc."
filed_at: "2026-02-23T23:59:59+00:00"
generated_at: "2026-05-16T01:13:59.187501+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# The Oncology Institute appoints Kim Tzoumakas to Board of Directors

## Summary
- Appointed Kim Tzoumakas, CEO of VytlOne National Pharmacy Services, to board effective Feb. 23, 2026.
- Ms. Tzoumakas previously led 21st Century Oncology through a turnaround and strategic sale; serves on multiple healthcare boards.
- She will receive $75k annual cash retainer paid quarterly plus restricted stock units for board service.
- She was not initially assigned to any board committees; term expires at 2027 annual meeting.

## SEC filing metadata
- accession: 0001553350-26-000007
- form_type: 8-K
- ticker: TOI
- cik: 0001799191
- company_name: Oncology Institute, Inc.
- filed_at: 2026-02-23T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799191/000155335026000007/0001553350-26-000007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799191/000155335026000007/toi_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001553350-26-000007
- JSON: https://secwatch.observer/filing/0001553350-26-000007.json
- Plain text: https://secwatch.observer/filing/0001553350-26-000007.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.